At the operating level, EBITDA jumped 43% to ₹490.4 crore in the first quarter of this fiscal over ₹343 crore in the corresponding period in the previous fiscal. EBITDA margin stood at 22.6% in the reporting quarter as compared to 18.4% in the corresponding period in the previous fiscal.
Also Read: Fortis Healthcare’s IHL gets ₹76.19 crore tax demand, plans to appealThe company reported hospital business revenues of ₹1,838 crore for Q1 FY26, marking an 18.6% increase over the same quarter last year. The operating EBITDA margin for the hospital segment stood at 22.1%, up from 18.5% in Q1 FY25. Revenue growth was driven by a rise in Average Revenue Per Occupied Bed (ARPOB) and a 7.8% increase in occupied beds compared to the previous year.
International patient revenue rose 21% year-on-year to ₹154 crore, contributing 7.9% to the overall hospital business revenue, up slightly from 7.8% in Q1 FY25. Volumes in key surgical procedures saw significant growth, with robotic surgeries up 75%, radiation therapy by 53%, and orthopaedic procedures increasing by 22% year-on-year.
In July 2025, Fortis signed an Operation and Maintenance (O&M) Services agreement with Gleneagles India. Under this agreement, Fortis will manage operations of approximately 700 beds across five hospitals and one clinic within the Gleneagles India network, strengthening its presence in metro cities.
Also Read: Fortis Healthcare shares jump 10%, top Nifty 500 gainer on strong management guidance
As of June 30, 2025, Fortis Healthcare’s net debt stood at ₹1,869 crore. The net debt to EBITDA ratio rose to 0.92x compared to 0.22x a year earlier, based on annualised Q1 EBITDA. Net debt to equity also increased to 0.20x from 0.04x. The rise in debt was due to funds raised for acquiring a 31.5% private equity stake in Agilus Diagnostics and for purchasing the ‘Fortis’ brand and trademarks.
In the diagnostics segment, gross revenue for Q1 FY26 stood at ₹368.8 crore, up 7.4% from ₹343.5 crore in Q1 FY25. Operating EBITDA margin based on gross revenue rose to 23.0%, compared to 16.1% in the same period last year. Excluding one-offs, the margin in Q1 FY25 was 18.7%.
Agilus Diagnostics continued to expand its network, with total customer touch points (CTPs) reaching 4,261 as of June 30, 2025. The business conducted approximately 10.13 million tests during the quarter, compared to 9.57 million in Q1 FY25. Revenue from the preventive portfolio within Agilus grew by 8.4% year-on-year.
Also Read: Fortis Healthcare Q4 net profit up 3% at ₹184 crore; declares dividend
The results came after the close of the market hours. Shares of Fortis Healthcare Ltd ended at ₹857.70, down by ₹9.70 or 1.12% on the BSE.
Also Watch | Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare discusses April-June quarter 2025 (Q1FY26) figures in an interview with CNBC-TV18.
